Kadmon Holdings Price to Book Ratio 2015-2021 | KDMN

Historical price to book ratio values for Kadmon Holdings (KDMN) over the last 10 years. The current price to book ratio for Kadmon Holdings as of October 15, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Kadmon Holdings Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-15 8.73 44.88
2021-06-30 3.87 $0.19 19.90
2021-03-31 3.89 $0.34 11.29
2020-12-31 4.15 $0.68 6.14
2020-09-30 3.92 $0.83 4.75
2020-06-30 5.12 $0.95 5.37
2020-03-31 4.19 $0.87 4.83
2019-12-31 4.53 $1.04 4.37
2019-09-30 2.52 $0.62 4.08
2019-06-30 2.06 $1.09 1.89
2019-03-31 2.64 $0.97 2.72
2018-12-31 2.08 $0.78 2.66
2018-09-30 3.34 $1.13 2.95
2018-06-30 3.99 $1.23 3.25
2018-03-31 4.25 $0.10 42.16
2017-12-31 3.62 $0.02 161.61
2017-09-30 3.35 $0.07 45.70
2017-06-30 3.89 $-0.74 -5.27
2017-03-31 3.62 $-0.38 -9.57
2016-12-31 5.35 $-0.56 -9.57
2016-09-30 7.34 $-0.19 -37.76
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.505B $0.008B
Kadmon Holdings Inc. is a biopharmaceutical company. It discovers, develops and delivers transformative therapies for unmet medical needs. The company's product pipeline includes KD025, KD045 and KD033 which are in clinical satge. Kadmon Holdings Inc. is based in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00